The results of the ABSORB III trial were within the prespecified margin for noninferiority with regards to the primary end point of target-lesion failure, which researchers defined as cardiac death, target-vessel MI or ischemia-driven target-lesion revascularization.

A meta-analysis of five randomized controlled trials found that performing endovascular therapy with stent retrievers was safe and effective in managing acute ischemic stroke and led to a significant improvement in functional clinical outcomes compared with standard therapy.

Within two years following PCIs, 13.3 percent of subsequent scheduled noncardiac surgical procedures were cancelled, according to an analysis of all PCIs performed at the Veterans Affairs (VA) Healthcare System from fiscal year 2000 to 2010.

From Oct. 11 to 15, leaders in interventional cardiovascular medicine will gather in San Francisco for the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Cardinal Health completed its acquisition of Johnson and Johnson’s Cordis business on Oct. 4 for $1.944 billion, seven months after Cardinal Health announced its offer.

The FDA approved the combination of ambrisentan and tadalafil to reduce the risks of disease progression and hospitalization for worsening pulmonary arterial hypertension (PAH) and improve exercise ability.

Training and passion sit at the core of the University of Washington Medical Center heart team's mission. Learn how this national training site for Protected PCI with hemodynamic support is teaching: hands-on, in-depth, in-person, head to head.

The FDA sent a warning letter to St. Jude Medical regarding a facility in Atlanta where the company manufactures its CardioMEMS heart failure system. St. Jude Medical revealed the information in an 8-K filing to the Securities and Exchange Commission on Oct. 1.